TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives

Int J Mol Sci. 2022 Oct 2;23(19):11684. doi: 10.3390/ijms231911684.


The four TCGA-based molecular prognostic groups of endometrial carcinoma (EC), i.e., POLE-mutant, mismatch repair (MMR)-deficient, p53-abnormal, and “no specific molecular profile” (NSMP), have recently been integrated into ESGO-ESTRO-ESP guidelines. The POLE-mutant and MMR-deficient groups are associated with high mutational load, morphological heterogeneity, and inflammatory infiltration. These groups are frequent in high-grade endometrioid, undifferentiated/dedifferentiated, and mixed histotypes. POLE-mutant ECs show good prognosis and do not require adjuvant treatment, although the management of cases at stage >II is still undefined. MMR-deficient ECs show intermediate prognosis and are currently substratified based on clinicopathological variables, some of which might not have prognostic value. These groups may benefit from immunotherapy. P53-mutant ECs are typically high-grade and often morphologically ambiguous, accounting for virtually all serous ECs, most carcinosarcomas and mixed ECs, and half of clear-cell ECs. They show poor prognosis and are treated with chemoradiotherapy; a subset may benefit from HER2 inhibitors or PARP inhibitors. The NSMP group is the most frequent TCGA group; its prognosis is highly variable and affected by clinicopathological/molecular factors, most of which are still under evaluation. In conclusion, the TCGA classification has improved diagnosis, risk stratification, and management of EC. Further studies are needed to resolve the points of uncertainty that still exist.

Keywords: POLE; TCGA; endometrial carcinoma; histotype; microsatellite; mismatch-repair; molecular; p53; prognosis; treatment.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor
  • Carcinoma, Endometrioid* / pathology
  • Endometrial Neoplasms* / diagnosis
  • Endometrial Neoplasms* / genetics
  • Endometrial Neoplasms* / therapy
  • Female
  • Humans
  • Mutation
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Prognosis
  • Tumor Suppressor Protein p53 / genetics


  • Biomarkers, Tumor
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Tumor Suppressor Protein p53

Grants and funding

This research received no external funding.